Stryker Corp. Q2 2026 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. Stryker Corporation is a global leader in medical technologies operating in two reportable segments: MedSurg and Neurotechnology and Orthopaedics. In Q1 2026, the company reorganized its structure, creating a new "Ortho Tech" business combining orthopaedic instruments and robotics (Mako) portfolios. The filing reflects this new structure with recast historical data.
Key Financial Metrics
| Metric | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Net Sales | $6,589M | $6,022M | $12,609M | $11,888M |
| Gross Profit | $4,498M | $3,841M | $8,308M | $7,585M |
| Gross Margin | 68.3% | 63.8% | 65.9% | 63.8% |
| Operating Income | $1,659M | $1,113M | $2,595M | $1,950M |
| Operating Margin | 25.2% | 18.5% | 20.6% | 16.4% |
| Net Earnings | $1,276M | $884M | $2,021M | $1,538M |
| Diluted EPS | $3.30 | $2.29 | $5.23 | $3.98 |
| Cash from Operations (YTD) | $1,842M (vs. $1,361M YTD 2025) | |||
| Total Debt | $14,942M (Current: $750M; Long-term: $14,192M) | |||
| Cash & Equivalents | $3,391M |
Material Changes vs. Prior Period
- Revenue Growth: Q2 2026 sales increased 9.4% (9.0% constant currency) driven by higher unit volume across MedSurg and Orthopaedics. YTD sales grew 6.1% (5.0% constant currency).
- Margin Expansion: Gross margin improved significantly to 68.3% in Q2 (from 63.8% in 2025), primarily due to a $158M reversal of 2025 tariffs and lower amortization of inventory stepped-up to fair value. Operating margin expanded to 25.2% in Q2.
- Acquisitions: In May 2026, Stryker acquired Amplitude Vascular Systems (AVS) for $435M cash plus up to $400M in milestones. This contrasts with the $4.8B Inari acquisition in Q1 2025.
- Divestitures: The Spinal Implants business was sold in 2025; remaining sales in this category were nominal ($3M) in Q2 2026.
- Impairments: Goodwill and other impairments dropped to $1M in Q2 2026 from $55M in Q2 2025.
Outlook, Risks, and Unusual Items
- Cybersecurity Incident: Management highlighted a cybersecurity incident reported on March 11, 2026, which caused idle production time and higher manufacturing costs in the first half of 2026. This is cited as a risk to future results.
- Non-GAAP Adjustments: Adjusted operating margin for Q2 2026 was 27.4%, excluding items such as structural optimization charges ($95M), acquisition costs, and the tariff reversal.
- Capital Allocation: The company prioritizes acquisitions, dividends, and share repurchases. No share repurchases were made in the first six months of 2026. Dividends declared were $0.88 per share in Q2.
- Debt Management: In March 2026, the company repaid $1,000M of 3.500% senior unsecured notes. Total debt decreased from $15,859M at year-end 2025 to $14,942M.
- Legal & Regulatory: Ongoing proceedings include product liability, labor, and tax matters. The company accrues for probable losses but notes ultimate costs could differ materially.
Investor Verification Checklist
- Tariff Reversal Impact: Verify the sustainability of the $158M tariff reversal benefit included in Q2 gross profit and its effect on future margin guidance.
- Cybersecurity Aftermath: Assess the full financial impact of the March 2026 cybersecurity incident on production capacity and supply chain costs beyond Q2.
- AVS Integration: Monitor the integration progress and regulatory approval timeline for the Amplitude Vascular Systems (AVS) intravascular lithotripsy platform.
- Organizational Restructuring: Confirm the long-term efficiency gains from the new "Ortho Tech" business structure and the reallocation of $518M in goodwill.
- Debt Maturities: Review the schedule of senior unsecured notes maturing between 2027 and 2030 to assess refinancing needs and interest rate exposure.